Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq futures outperform after Nvidia puts AI fears to rest
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil gains as traders weigh prospects of easing Middle East supply disruptions
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Dollar General stock jumps on earnings beat and raised guidance
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Alexion Pharmaceuticals (ALXN) PT Raised to $156 at Nomura/Instinet
March 15, 2018 1:45 PM EDTNomura/Instinet raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $156.00 (from $148.00) while maintaining a Buy rating.
Analyst Christopher Marai commented, "Alexion reported results from the P3 301 study of ALXN1210 in PNH-naïve patients. The study demonstrated non-inferiority across all co-primary and four key... More
Alexion Pharmaceuticals (ALXN) PT Raised to $160 at Baird
March 15, 2018 12:14 PM EDTBaird raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $160.00 (from $150.00) while maintaining a Outperform rating.
Analyst Michael E. Ulz commented, "Following the call, we remain encouraged by the Phase 3 PNH naïve results with ALXN1210 demonstrating non-inferiority on all six key endpoints with... More
Alexion Pharmaceuticals (ALXN) PT Raised to $151 at Raymond James
March 15, 2018 12:13 PM EDTRaymond James raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $151.00 (from $134.00) while maintaining an Outperform rating following data today.
... MoreRBC Sees 10-15% Move in Alexion Pharma (ALXN) Following ALXN-1210 Results
March 15, 2018 9:41 AM EDTRBC Capital analsyt Kennen MacKay was positive on Alexion Pharma (NASDAQ: ALXN) after ALXN-1210 hit its hurdle in the 1st of 2 Phase 3 trials.
MacKay called the results a "win, but note a full re-rate scenario." He sees a 10-15% move.
... MoreJPMorgan Reiterates Overweight on Alexion Pharma (ALXN) Following Phase 3 Results
March 15, 2018 9:06 AM EDTJPMorgan reiterated an Overweight rating and $176.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN) following the company's positive top-line results from the PNH naïve phase 3 study of ALXN1210 versus Soliris.
Analyst Anupam Rama believes that the data is "a clear win for ALXN1210 in... More
Alexion (ALXN) to See Releif Rally on ALXN-1210 Results - BMO
March 15, 2018 8:57 AM EDTBMO Capital analyst M. Ian Somaiya expects shares of Alexion Pharmaceuticals (NASDAQ: ALXN) trade higher as investors breathe a sigh of relief following release of Phase 3 ALXN-1210 data.
"The treatment naïve study met most investor expectations, meeting the non-inferiority primary endpoint (some... More
